Molecular Insight appoints CFO

Aug 15, 2007

Molecular Insight Pharmaceuticals of Cambridge, MA has appointed a new chief financial officer.

Donald Wallroth joins Molecular Insight from the national life sciences practice of Tatum, an executive financial services company. Prior to his work at Tatum, Wallroth was a partner at Keen Partners, an investment banking firm with a focus on life sciences.

He has also served as chief operating officer of GoldK and chief financial officer and chief operating officer at Transition Systems, a healthcare software company.

By AuntMinnie.com staff writers
August 16, 2007

Related Reading

Molecular Insight posts Q2 2007 results, August 13, 2007

Copyright © 2007 AuntMinnie.com

Latest in Nuclear Medicine
2024 10 28 Meningioma Thumbnail
Intraarterial PRRT safe in patients with meningioma
October 28, 2024
New! Imaging Life Issue 20 now available
Sponsored
New! Imaging Life Issue 20 now available
November 5, 2024
Prostate
How effective is Pluvicto in a ‘real-world’ setting?
September 20, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
SNMMI: PET-based protocol shows promise in radioligand therapy
June 12, 2024
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
2007 04 11 12 05 10 706
Nuclear Medicine
Is PET an endangered species?
2007 07 30 14 46 43 706
Nuclear Medicine
Interest surges in use of imaging for tracking radiation therapy
New! Imaging Life Issue 20 now available
Sponsor Content
New! Imaging Life Issue 20 now available
More in Nuclear Medicine
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
NNSA's Mo-99 program: A bumpy ride
By Will Morton
Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).
October 10, 2024
Mo 99
How effective is Pluvicto in a ‘real-world’ setting?
By Will Morton
Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.
September 20, 2024
Prostate
SNMMI: PET-based protocol shows promise in radioligand therapy
By Amerigo Allegretto
A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
The rise of theranostics: Part 3 -- What is a theranostics center?
By Liz Carey
For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.
June 3, 2024
Part3 Riseof Thernaostics Cover
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
SNMMI to tackle Capitol Hill
By AuntMinnie.com staff writers
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.
April 3, 2024
Us Flag
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 19, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Cannabis may influence bowel motility
By Will Morton
Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.
March 11, 2024
Cannabis
Hold off on the Egg McMuffins before GES tests, experts say
By Will Morton
Nuclear medicine technologists are being advised that not just any meal works for patients before gastric emptying scintigraphy (GES).
March 7, 2024
Stomach
Neiman HPI publishes advanced imaging prediction index
By Kate Madden Yee
The Harvey L. Neiman Health Policy Institute (HPI) has developed and released a comorbidity index designed to help predict use of advanced imaging.
January 25, 2024
2018 08 14 19 14 9213 Neiman Hip 400
Page 1 of 436
Next Page